الفهرس 
Epidemiologyيوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 154 |  |  |
| | | from | 154 | | |
المستخلص
Alzheimer’s disease (AD) poses a significant challenge as a neurodegenerative disorder, primarily affecting individuals aged 65 and above. The intricate nature of the
disease complicates the search for effective treatments. Currently, AD affects over 50 million
people globally, and this number is expected to triple by the year 2050. Consequently, there is
an urgent need for drug developers to discover effective anti-AD agents. Although the precise
mechanism of AD remains uncertain, it is widely recognized that the disease is a complex
syndrome resulting from various neurochemical factors. Several molecular mechanisms have
been proposed, including the β-amyloid cascade, cholinergic dysfunction, as well as various
other mechanisms and hypotheses that have been suggested and documented. The FDA has
authorized five drugs for AD symptom relief, four of which are acetylcholinesterase (AChE)
inhibitors: rivastigmine, galantamine, tacrine, and donepezil. Among these, donepezil stands
out as the most favorable AChE inhibitor due to its unique benefits. The 1,2,3-triazole and its
derivatives play a critical role as essential heterocyclic compounds extensively employed as
pharmacophores in pharmaceutical drugs and diverse fields. Their biological activities have
been extensively explored and validated through various studies. By incorporating donepeziltriazole
with a sugar moiety, these compounds demonstrate the ability to effectively target
and deliver drugs across the blood-brain barrier.